ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE: PS1184